🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Joel Greenblatt’s AKBA Holdings & Trades

First Buy
Q2 2021
Duration Held
6 Quarters
Largest Add
Q2 2021
+19,195 Shares
Current Position
27,172 Shares
$37,769 Value

Joel Greenblatt's AKBA Position Overview

Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 27,172 shares of Akebia Therapeutics, Inc. (AKBA) worth $37,769, representing 0.00% of the portfolio. First purchased in 2021-Q2, this short-term holding has been held for 6 quarters.

Based on 13F filings, Joel Greenblatt has maintained this position in AKBA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 15,569 shares. Largest reduction occurred in Q3 2021, reducing 19,195 shares.

Analysis based on 13F filings available since 2013 Q2

Joel Greenblatt's Akebia Therapeutics (AKBA) Holding Value Over Time

Track share changes against reported price movement

Quarterly Akebia Therapeutics (AKBA) Trades by Joel Greenblatt

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +11,202 Add 70.14% 27,172 $1.39
Q4 2025 +1,471 Add 10.15% 15,970 $1.61
Q3 2025 -1,070 Reduce 6.87% 14,499 $2.73
Q2 2025 +15,569 New Buy 15,569 $3.64
Q3 2021 -19,195 Sold Out 0 $0.00
Q2 2021 +19,195 New Buy 19,195 $3.80

Joel Greenblatt's Akebia Therapeutics Investment FAQs

Joel Greenblatt first purchased Akebia Therapeutics, Inc. (AKBA) in Q2 2021, acquiring 19,195 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt has held Akebia Therapeutics, Inc. (AKBA) for 6 quarters since Q2 2021.

Joel Greenblatt's largest addition to Akebia Therapeutics, Inc. (AKBA) was in Q2 2021, adding 19,195 shares worth $73,000.

According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 27,172 shares of Akebia Therapeutics, Inc. (AKBA), valued at approximately $37,769.

As of the Q1 2026 filing, Akebia Therapeutics, Inc. (AKBA) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.

Joel Greenblatt's peak holding in Akebia Therapeutics, Inc. (AKBA) was 27,172 shares, as reported at the end of Q1 2026.